Sol-Gel Technologies

73 articles about Sol-Gel Technologies

• Sol-Gel Technologies Reports Third Quarter 2023 Financial Results and Provides Corporate Update

  11/9/2023

  Sol-Gel Technologies, Ltd. announced financial results for the third quarter ended September 30, 2023 and provided a corporate update.

• Sol-Gel Technologies Reports Second Quarter 2023 Financial Results and Provides Corporate Update

  8/10/2023

  Sol-Gel today announced financial results for the second quarter ended June 30, 2023 and provided a corporate update.

• Sol-Gel and Searchlight Pharma Announce Licensing Agreements to Commercialize TWYNEO® and EPSOLAY® in Canada

  6/6/2023

  Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel”), an Israel-based dermatology company and Searchlight Pharma Inc. (“Searchlight”), a private Canadian specialty pharmaceutical company, today announced the signing of exclusive license agreements for TWYNEO and EPSOLAY for the Canadian market.

• Sol-Gel Technologies Reports First Quarter 2023 Financial Results and Provides Corporate Update

  5/12/2023

  Sol-Gel Technologies, Ltd., a dermatology company with two innovative dermatology products, EPSOLAY and TWYNEO, that were launched in the U.S., SGT-610, which is Phase 3-ready, and an earlier-stage SGT-210, announced financial results for the first quarter ended March 31, 2023 and provided a corporate update.

• Sol-Gel Technologies to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference

  3/20/2023

  Sol-Gel Technologies, Ltd. today announced that it will present at H.C. Wainwright’s Autoimmune & Inflammatory Disease Virtual Event on Thursday, March 30, 2023.

• Sol-Gel Reports Full-Year 2022 Financial Results and Corporate Developments

  3/10/2023

  Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company with two innovative dermatology products that were launched in the U.S. and an innovative pipeline, today announced financial results for the full year ended December 31, 2022 and provided a corporate update.

• Sol-Gel Announces Aggregate $22.8 Million Concurrent Registered Direct and Private Placement Offerings

  1/27/2023

  Sol-Gel Technologies, Ltd. announced today the pricing of a registered direct offering with Armistice Capital for the sale and purchase of 2,560,000 shares of the Company’s ordinary shares, par value NIS 0.1 (the “Ordinary Shares”), at a purchase price of $5.00 per share, in a registered direct offering (the “Registered Direct Offering”).

• Sol-Gel Acquires Patidegib, a Phase 3, FDA-Breakthrough-Designated Orphan Product Candidate to Pursue Potential Market of Over $300 Million

  1/27/2023

  Sol-Gel Technologies, Ltd. announced today the acquisition of topically-applied patidegib, a hedgehog signaling pathway blocker, for the treatment of Gorlin syndrome from PellePharm, Inc.

• Sol-Gel Technologies Reports Third Quarter 2022 Financial Results and Provides Corporate Update

  11/10/2022

  Sol-Gel Technologies, Ltd., a dermatology company focused on identifying, developing, commercializing or partnering branded and generic topical drug products for the treatment of skin diseases, announced financial results for the third quarter ended September 30, 2022 and provided a corporate update.

• Sol-Gel Technologies Appoints Michael Glezin Vice President, Business Development

  10/3/2022

  Sol-Gel Technologies, Ltd. announced today the appointment of Michael Glezin to the position of Vice President, Business Development.

• Sol-Gel Technologies Reports Second Quarter 2022 Financial Results and Provides Corporate Update

  8/4/2022

  Sol-Gel Technologies, Ltd., a dermatology company focused on identifying, developing, commercializing or partnering branded and generic topical drug products for the treatment of skin diseases, announced financial results for the second quarter ended June 30, 2022 and provided a corporate update.

• Sol-Gel Technologies to Participate in the 2022 Jefferies Global Healthcare Conference

  6/1/2022

  Sol-Gel Technologies, Ltd. announced that Chief Executive Officer, Alon Seri-Levy, will present a corporate update at the 2022 Jefferies Global Healthcare Conference to be held June 8 -10, 2022 in-person, in New York, NY.

• Sol-Gel Technologies to Present in Upcoming H.C. Wainwright Global Investment Conference

  5/17/2022

  Sol-Gel Technologies, Ltd. announced that that the Company will present at the upcoming H.C. Wainwright Global Investment Conference being held May 23-26, 2022.

• Sol-Gel Technologies Reports First Quarter 2022 Financial Results and Provides Corporate Update

  5/13/2022

  Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded and generic topical drug products for the treatment of skin diseases, announced today financial results for the first quarter ended March 31, 2022 and provided a corporate update.

• 

  Global Roundup: Exogene Secures Funding to Support TCR Discovery

  4/28/2022

  Exogene nets $2 million to propel the development of its AI platform for T-cell receptor discovery and Healome spins out to deploy a 'pro-healing' platform with a focus on ocular surface diseases.

• Sol-Gel Technologies and Galderma Announce FDA Approval of EPSOLAY®

  4/25/2022

  Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, announced today the Food and Drug Administration (FDA) approval of its drug product, EPSOLAY®, a proprietary cream formulation of benzoyl peroxide, 5%, for the treatment of inflammatory lesions of rosacea in adults.

• Sol-Gel Technologies Announces the Commercial Availability of TWYNEO®

  4/14/2022

  Sol-Gel Technologies, Ltd. announced that TWYNEO®, a topical cream containing a fixed‑dose combination of tretinoin, 0.1%, and benzoyl peroxide, 3% for the treatment of acne vulgaris in adults and pediatric patients nine years of age and older, is now available for purchase by consumers who obtain a prescription from their physician.

• Sol-Gel Technologies Reports Full Year 2021 Financial Results and Corporate Developments

  3/30/2022

  Sol-Gel Technologies, Ltd. today announced financial results for the full year ended December 31, 2021, and provided recent corporate updates.

• Sol-Gel Technologies Announces U.S. Commercial Partner Galderma to Promote TWYNEO® at the American Academy of Dermatology Annual Meeting to be Held March 25-29 in Boston

  3/25/2022

  Sol-Gel Technologies, Ltd.  today announced that its U.S. commercialization partner, Galderma, will be promoting TWYNEO (tretinoin and benzoyl peroxide) Cream, 0.1%/3% at the American Academy of Dermatology (AAD) Annual Meeting, March 25-29, 2022, in Boston, Massachusetts.

• Sol-Gel Technologies to Participate in Upcoming LifeSci Partners Corporate Access Event and H.C. Wainwright BioConnect 2022 Healthcare Conference

  12/22/2021

  Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that the Company will participate in the LifeSci Partners 11th Annual Corporate Access Event and the H.C. Wainwright BioConnect Conference.